A Lazy Man's Program To The Methisazone Triumph

In the IFM trial, significant prolongation of PFS was seen but this did not result in longer OS. Toxicity of bortezomib: Bortezomib requires intravenous administration. The most frequently reported toxicities are shown in Table?IX. All are predictable but require active management and specific guidelines have been developed for their prevention and treatment. A proforma for the early detection of side-effects for use in patients on bortezomib therapy has been developed and is shown in Appendix IV. The key to effective use of bortezomib is the optimal management of treatment http://www.selleckchem.com/products/bay-57-1293.html emergent toxicities allowing the maximum duration of therapy. Recent data from front line protocols incorporating bortezomib suggest that a weekly regimen is as effective and associated with less neuropathy than twice weekly regimens (Gay et?al, 2009; Mateos et?al, 2010). In all the trials described above, stem cell mobilization was unaffected by bortezomib therapy and haematological recovery was adequate following stem cell reinfusion after high dose therapy. Neutropenia secondary to bortezomib is unusual, but thrombocytopenia is a frequent cyclical effect with nadirs around day 11, which usually recover towards baseline by the start of the next cycle. The platelet count should be >30?��?109/l to treat and patients may receive platelet transfusions to allow this. If the platelet count is http://en.wikipedia.org/wiki/Methisazone be considered e.g. to 1?mg/m2. Thrombocytopenia tends to become less severe with time on treatment. There are no recommended dose reductions for patients with renal or hepatic impairment. Aciclovir prophylaxis is recommended due to increased incidence of varicella zoster infection. Venous thromboembolic events are not a feature with bortezomib either alone or in combination and hence prophylaxis is not required. Lenalidomide (Revlimid) is an orally administered thalidomide analogue with a different side-effect profile. It has more potent in-vitro activity, including the inhibition of angiogenesis, cytokine modulation and T-cell co-stimulation than thalidomide (Corral & Kaplan, 1999; Hideshima et?al, 2000; Haslett et?al, 2003). Evidence for http://www.selleckchem.com/products/Roscovitine.html use of lenalidomide-containing regimens as induction prior to SCT Several phase II studies of lenalidomide with dexamethasone +/? chemotherapy have demonstrated high response rates of between 76 and 91% and are summarized in Appendix III (Table?3). In a study of 34 patients treated with a combination of lenalidomide 25?mg daily on days 1�C21 of a 28-day cycle and high dose dexamethasone, all patients who underwent stem cell mobilization collected sufficient stem cells. (Rajkumar et?al, 2005). Despite this, concerns have been raised about failure to harvest adequate stem cells after prolonged lenalidomide treatment and, as a result, it is now recommended that stem cells should be collected within 6?months of initiation of lenalidomide therapy (Kumar et?al, 2007).